Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: OXYCONTIN

« Back to Dashboard
Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from ten suppliers. There are thirteen patents protecting this drug and seven Paragraph IV challenges.

This drug has three hundred and ninety-nine patent family members in forty-four countries.

The generic ingredient in OXYCONTIN is oxycodone hydrochloride. There are seventeen drug master file entries for this compound. Eighteen suppliers are listed for this compound. There are six tentative approvals for this compound. Additional details are available on the oxycodone hydrochloride profile page.

Summary for Tradename: OXYCONTIN

Patents:13
Applicants:1
NDAs:1
Suppliers / Packagers: see list78
2013 Sales:$2,534,909,000

Pharmacology for Tradename: OXYCONTIN

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists

Clinical Trials for: OXYCONTIN

Pharmacokinetics Study of ALO-02 and OxyContin
Status: Completed Condition: Management of Moderate to Severe Pain

Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia
Status: Recruiting Condition: Postoperative Pain Management; Radical Cystectomy; Epidural Analgesia; Oral Oxycodone With/Without Naloxone; Return of the Bowel Function

Study of PF614 Compared to OxyContin® in Healthy Volunteers
Status: Not yet recruiting Condition: Healthy

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone
Status: Completed Condition: Pain

A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients
Status: Completed Condition: Cancer

Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans
Status: Completed Condition: Effects of 2 Mu-opiates on Gastrointestinal Transit

Oxycodone Versus Intravenous Morphine for Postoperative Analgesia After Hip Surgery
Status: Recruiting Condition: Arthroplasty, Replacement, Hip

A Open-label, Single-dose Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers
Status: Completed Condition: Healthy

Abuse Liability of Controlled-Release Oxycodone Formulations
Status: Completed Condition: Substance-Related Disorders

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Status: Completed Condition: Healthy Volunteers

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-005Apr 5, 2010RXYes8,337,888<disabled>Y <disabled>
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-007Apr 5, 2010RXNo<disabled><disabled>
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-003Apr 5, 2010RXNo6,488,963<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OXYCONTIN

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-004Apr 5, 20105,508,042<disabled>
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-007Apr 5, 20105,508,042<disabled>
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-001Apr 5, 20105,508,042<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: OXYCONTIN

Drugname Dosage Strength RLD Submissiondate
oxycodone hydrochlorideExtended-release Tablet40 mgOxyContin (NDA 022272)10/4/2010
oxycodone hydrochlorideExtended-release Tablet30 mg, 60 mg and 80 mgOxyContin (NDA 022272)10/18/2010
oxycodone hydrochlorideExtended-release Tablet20 mgOxyContin (NDA 022272)10/29/2010
oxycodone hydrochlorideExtended-release Tablet15 mgOxyContin (NDA 022272)10/28/2010
oxycodone hydrochlorideExtended-release Tablet10 mgOxyContin (NDA 022272)10/25/2010
oxycodone hydrochlorideExtended-release Tablets15 mgOxycontin2/15/2007
oxycodone hydrochlorideExtended-release Tablets30 mg and 60 mgOxycontin1/3/2007

International Patent Family for Tradename: OXYCONTIN

Country Document Number Publication Date
Slovenia1699440Mar 31, 2010
European Patent Office1859789Nov 28, 2007
Peru11842009Aug 03, 2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc